VERDE SCIENCE PURSUING DEVELOPMENT OF PROMISING POINT-OF-CARE
EBOLA SCREENING TEST
Richmond, BC, Nov 10, 2014. (OTCPK: VRCI) Verde Science, Inc., a
Medical Research and Development Company focused on novel effective
treatments for emerging and contemporary health issues, is pleased
to announce that it is working with three new members of its
R&D team in Canada and India to develop an easily administered
point-of-care test for screening for Ebola and other closely
related viruses. Following basic research Verde expects to
develop a point-of-care testing kit that will enable health care
practitioners to effectively screen for Ebola sometime in 2015.
According to Manit Patel, Verde Science Chief Technology
Officer, “A shortage of specialized labs capable of handling
potentially infected blood samples has made it difficult to track
the Ebola outbreak. Our research is focused on developing a
panel of tests to enable 1) simple point of care detection that
will not require samples to be transported to specialized labs, and
2) molecular characterization of the detected viruses to allow
differentiation of closely related viruses and identification of
specific strains. Early detection and characterization of the
pathogen is critical to containment of any infection.”
In line with its over arching vision, Verde Science’s current
pipeline of research includes the isolation of active compounds
from the marijuana plant for the treatment of specific medical
conditions through pharmaceutical dosage formulations and
diagnostic screening kits. Harp Sangha, Verde’s CEO stated, “This
new development demonstrates the effectiveness of our model.
By creating alliances with brilliant scientists and medical product
developers world-wide, incorporating them into our overarching
R&D structure, and applying professional administrative and
financing techniques, we will be able to bring important medical
breakthroughs to market in an expedited and cost-effective
manner. We are in the process of screening capital raising
opportunities for this and other projects and we are confident of
our ability to fund our research under very acceptable terms.”
About Verde Science, Inc. (VRCI)
Verde Science, Inc. (www.VerdeScienceInc.com) is a
public company trading under the symbol OTCPK: VRCI. The
Company is focused on Medical Research and Development, which
includes medical marijuana research and the development of
effective treatments for emerging and contemporary health issues
that have been inadequately addressed.
Safe Harbor Statements?Certain information contained in this
news release constitutes "forward-looking statements" as such term
is used in applicable United States and Canadian laws. Generally,
these forward-looking statements can be identified by the use of
forward-looking terminology such as "expects" or "does not expect",
"is expected", "anticipates" or "does not anticipate", "plans",
"estimates", "intends" or "believes", or that certain actions,
events or results "may", "could", "would", "might" or "will be
taken", "occur", or "be achieved". Forward-looking statements
are based on the opinions and estimates of management as of the
date such statements are made, and are subject to known and unknown
risks, uncertainties and other factors that may cause the actual
results, performance or achievements of the Company to be
materially different from those expressed or implied by such
forward-looking statements. Many of these factors are beyond the
Company's ability to control or predict. Important factors that may
cause actual results to differ materially and that could impact the
Company and the statements contained in this news release can be
found in the Company's filings with the SEC. Such risks and other
factors include, among others, the ability to locate and acquire
suitable interests in alternative medicine manufacturing operations
on terms acceptable to the Company, the availability of financing
on acceptable terms, accidents, labor disputes, acts of God and
other risks of the alternative medicine industry including, without
limitation, delays in obtaining governmental approvals or permits,
title disputes or claims limitations on insurance coverage. The
Company believes that the expectations reflected in the
forward-looking statements included in this news release are
reasonable; however, no assurance can be given that these
expectations will prove to be correct, and such forward-looking
statements should not be unduly relied upon. The Company assumes no
obligation to update or supplement any forward-looking statements
whether as a result of new information, future events or
otherwise.
For further information please see our investor profile available
on our website (www.verdescienceinc.com) or
contact:
Harp Sangha, Chairman/CEO
1-858-210-0236
harpsangha@shaw.ca
Louis Silver, Director of Investor Relations
610-710-1303
lsilver@verdescienceinc.com
https://twitter.com/verdescience